Establishment Labs Holdings Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; this is an annual report, not a standalone fourth-quarter filing. The company develops and sells medical devices for aesthetic and reconstructive surgery, with silicone gel-filled Motiva breast implants accounting for approximately 98% of 2020 revenue. Its products were sold in more than 80 countries, but Motiva implants were not approved for commercial sale in the United States.
Key financial results
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $84.7 million | $89.6 million | Down 5.5% |
| Gross profit / margin | $52.5 million / 62.0% | $54.9 million / 61.3% | Gross profit down $2.4 million; margin up 0.7 percentage points |
| Operating expenses | $80.4 million | $85.8 million | Down $5.4 million |
| Operating loss | $27.9 million | $30.9 million | Loss narrowed $3.0 million |
| Net loss | $38.1 million | $38.2 million | Nearly unchanged |
| Basic and diluted loss per share | $1.63 | $1.86 | Loss per share narrowed |
| Net cash used in operating activities | $12.5 million | $30.0 million | Cash use reduced by $17.5 million |
| Cash at year-end | $84.5 million | $37.7 million | Up $46.9 million |
2020 gross margin improved mainly due to geographic mix, manufacturing efficiencies and planning, partly offset by higher inventory obsolescence and scrap. The company reported a $165.2 million accumulated deficit. Current assets were $132.3 million against current liabilities of $25.9 million. Management said available cash, operating cash and the February 2020 offering proceeds were expected to cover liquidity needs for at least 12 months, while cautioning that assumptions could prove wrong.
Cash from financing was $64.7 million, chiefly reflecting $63.9 million in net proceeds from a February 2020 follow-on share offering. Investing cash use was $5.6 million. The filing reports $65.0 million of Madryn debt principal, with a $49.8 million net carrying value after debt discount and issuance costs. No principal is due until September 30, 2025. The agreement is secured by substantially all assets, includes minimum revenue and liquidity requirements, and restricts additional debt and other actions. The company reported compliance with financial covenants at year-end. Its reported Madryn interest terms include an 18.4% effective rate and an approximately 10.6% weighted-average rate at December 31, 2020.
Material changes versus FY2019
- COVID-19-related elective procedure restrictions drove the annual revenue decline, with the largest impact in the second quarter. Management said third- and fourth-quarter revenue recovered to levels comparable to or above the corresponding 2019 quarters.
- SG&A fell 5.9% to $66.6 million; R&D fell 8.0% to $13.8 million, partly reflecting cost controls and delayed reconstruction-cohort clinical enrollment.
- Operating cash use improved substantially, in part alongside lower operating costs and favorable working-capital movements; the company also raised equity capital through the follow-on offering.
- Inventory reserves rose to $1.6 million from $0.3 million. Foreign currency transaction losses increased to $1.7 million from $1.2 million, primarily reflecting Brazilian real weakness.
Outlook, risks and notable items
- Outlook: Management expects continued losses in the intermediate term and anticipates that 2021 results could be materially affected by COVID-19, but said the impact could not be reasonably estimated. No specific revenue or earnings guidance was provided.
- Products and regulation: The company received CE marks in 2020 for the Ergonomix2 implant platform and Motiva Flora tissue expander. It expected to begin Ergonomix2 commercialization in Europe in the first half of 2021 and expand to other CE-mark markets later in 2021. Motiva MIA tools remained subject to regulatory approval. The U.S. IDE study had completed aesthetic-cohort surgeries, while reconstruction enrollment continued; the company estimated total study costs of $30–$40 million over ten years. COVID-related delays could add at least six months to the planned regulatory timeline. U.S. commercialization depends on FDA PMA approval, which is uncertain.
- Capacity plans: A proposed Costa Rica facility expansion was estimated at $35.3 million, with potential initial added capacity of about 400,000 units annually and up to 800,000 with a further $4.6 million equipment investment. The project remained in design, subject to board approval and definitive agreements.
- Major risks: Pandemic-driven procedure deferrals and economic weakness; FDA and international approval and clinical-trial uncertainty; competition; dependence on NuSil as the sole supplier of medical-grade silicone (supply agreement due to expire in December 2021); currency volatility; and product-liability, safety, and reputational risks. The company’s post-market adverse-event figures are self-reported and not based on mandatory follow-up or an FDA PMA study, so they are not directly comparable to competitors’ prospective trial data.
- Controls and reporting: Management concluded disclosure controls and internal control over financial reporting were not effective at December 31, 2020. A previously reported material weakness involving review of the manual consolidation process remained unremediated. The independent auditor gave an unqualified opinion on the financial statements, but was not engaged to opine on internal-control effectiveness.
- Other items: No material legal proceedings or off-balance-sheet arrangements were reported. The company reported no cash dividends and no share repurchases in the fourth quarter. A $35.3 million facility project is a plan, not a completed commitment.
Important facts for investors to verify
- Whether post-pandemic procedure volumes, revenue and cash conversion remain resilient, and whether reported quarterly recovery continued after year-end.
- Cash burn, working-capital trends, covenant headroom and the assumptions behind management’s stated minimum 12-month liquidity outlook.
- Progress on the FDA IDE study, reconstruction enrollment, PMA timing and total clinical-trial spending.
- Renewal or replacement of the NuSil silicone supply agreement before its December 2021 expiration.
- Whether the manual-consolidation material weakness is remediated and disclosure controls improve.
- Actual approval, launch timing, investment and capacity outcomes for Ergonomix2, Motiva MIA and the proposed Costa Rica expansion.
- Inventory reserve adequacy, foreign-exchange exposure and the quality and comparability of safety data used in product claims.